(Q39735076)

14 September 2017

title

The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy (English)

1 reference

14 September 2017

The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti–CTLA-4 Therapy (English)

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

5 December 2024

Tihui Fu

1 reference

14 September 2017

Qiuming He

series ordinal

1 reference

14 September 2017

Padmanee Sharma

series ordinal

1 reference

14 September 2017

language of work or name

English

0 references

publication date

27 June 2011

1 reference

full work available at URL

14 September 2017

https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_The_ICOS_ICOSL_Pathway_Is_Required_for_Optimal_Antitumor_Responses_Mediated_by_Anti_CTLA-4_Therapy/22388831/1/files/39834320.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21708958

https://aacrjournals.org/cancerres/article-pdf/71/16/5445/2651424/5445.pdf

5 December 2024

file format

Portable Document Format

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

5 December 2024

1 reference

14 September 2017

1 reference

14 September 2017

1 reference

14 September 2017

page(s)

5445-5454

1 reference

CTLA-4 can function as a negative regulator of T cell activation

14 September 2017

cites work

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1016/1074-7613(94)90071-X

CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

5 December 2024

The B7-CD28 superfamily

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Enhancement of antitumor immunity by CTLA-4 blockade

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Checkpoint blockade in cancer immunotherapy

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

ICOS costimulation: It's not just for TH2 cells anymore

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Costimulation through the inducible costimulator ligand is essential for both T helper and B cell functions in T cell-dependent B cell responses

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

ICOS co-stimulatory receptor is essential for T-cell activation and function

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity.

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

ICOS mediates the development of insulin-dependent diabetes mellitus in nonobese diabetic mice

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

ICOS controls effector function but not trafficking receptor expression of kidney-infiltrating effector T cells in murine lupus

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Heteroclitic immunization induces tumor immunity

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Control of regulatory T cell development by the transcription factor Foxp3

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

ICOS controls the pool size of effector-memory and regulatory T cells.

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Interferon-gamma and cancer immunoediting

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Regulatory roles of IL-2 and IL-4 in H4/inducible costimulator expression on activated CD4+ T cells during Th cell development

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Potent activity of soluble B7RP-1-Fc in therapy of murine tumors in syngeneic hosts.

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Comparable in vivo efficacy of CD28/B7, ICOS/GL50, and ICOS/GL50B costimulatory pathways in murine tumor models: IFNgamma-dependent enhancement of CTL priming, effector functions, and tumor specific memory CTL.

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

B7H costimulates clonal expansion of, and cognate destruction of tumor cells by, CD8(+) T lymphocytes in vivo

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Enhancement of CD8+ T cell responses by ICOS/B7h costimulation

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

Down-regulation of ICOS ligand by interaction with ICOS functions as a regulatory mechanism for immune responses

5 December 2024

1 reference

https://api.crossref.org/works/10.1158/0008-5472.CAN-11-1138

5 December 2024

Identifiers

DOI

1 reference

14 September 2017

1 reference